GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » Dividend Payout Ratio

QNCX (Quince Therapeutics) Dividend Payout Ratio : 0.00 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Quince Therapeutics's Dividend Payout Ratio for the months ended in Sep. 2024 was 0.00.

The historical rank and industry rank for Quince Therapeutics's Dividend Payout Ratio or its related term are showing as below:


QNCX's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.45
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-03-19), the Dividend Yield % of Quince Therapeutics is 0.00%.

Quince Therapeutics's Dividends per Share for the months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Quince Therapeutics Dividend Payout Ratio Historical Data

The historical data trend for Quince Therapeutics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics Dividend Payout Ratio Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Payout Ratio
Get a 7-Day Free Trial - - - - -

Quince Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Quince Therapeutics's Dividend Payout Ratio

For the Biotechnology subindustry, Quince Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quince Therapeutics's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Dividend Payout Ratio falls into.



Quince Therapeutics Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Quince Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2023 )/ EPS without NRI (A: Dec. 2023 )
=0/ -0.64
=N/A

Quince Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Sep. 2024 )/ EPS without NRI (Q: Sep. 2024 )
=0/ -0.179
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quince Therapeutics (NAS:QNCX) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Quince Therapeutics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Quince Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Executives
Dirk Thye director, officer: Chief Executive Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah officer: Chief Business Officer 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Charles S. Ryan officer: President C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
David Lamond director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer officer: Chief Scientific Officer 601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Margaret Mcloughlin director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon officer: Chief Accounting Officer C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray director C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell officer: Chief Legal & Adm. Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Philip S Low director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Karen L. Smith officer: Chief Medical Officer C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy director, officer: Chief Scientific Officer C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe officer: Chief Financial Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258